A year has passed since the Ministry of Health, Labor and Welfare (MHLW) announced its package strategy to fuel the early commercialization of software as a medical device (SaMD) in November last year. A growing number of drug makers are…
HOME > COLUMN
COLUMN
- Think Differently for Post-Pandemic Success
August 14, 2020
- The Crisis That Ignited a Workplace Revolution
July 6, 2020
- Smart Strategies for Building Your Dream Team
March 17, 2020
- A Peek into the Digital Pharmaceutical Industry
November 21, 2019
- Plant the Seeds of Success when Battling a Crisis
September 30, 2019
- Practice Makes Perfect - Even in Marketing!
August 19, 2019
- Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
- Big Question Mark to Pricey Drug Bashing
July 12, 2019
- The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
- The Power in Teaching Your Team “How to Speak”
May 28, 2019
- Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
- No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
- 6 Core Elements of Recruitment Mastery
March 22, 2019
- Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
- Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
- Expat Truths from the Japanese Medical Device World
December 3, 2018
- Why Did the Project Take so Long?
November 16, 2018
- Finding Captains in Your Organization
October 12, 2018
- Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
- How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
ページ
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…